Search results
Results From The WOW.Com Content Network
Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 105,000 sq. ft. area at Dholka, Gujarat, India which is staffed by 300 scientists. [citation needed] The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma.
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. [8]In 1995, the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals, and Cadila Healthcare became the Patel family's holding company.
Gujarat has become a hub for the pharmaceutical industry, with several established companies such as Torrent Pharmaceuticals, Zydus Lifesciences, Cadila Pharmaceuticals, Alembic Pharmaceuticals, Sun Pharma, Claris, Intas Pharmaceuticals, and Dishman Pharmaceuticals having operations in the state.
Indravadan Ambalal Modi (18 February 1926 – 26 November 2012) [1] was an Indian pharmaceuticals industrialist who founded Cadila Pharmaceuticals in Ahmedabad.He is popularly known as the 'Medicine Man of India' for his contribution to the pharmaceutical industry of India post independence.
Cadila's stake in the company increased to over 70% in 2008, after the merger of Cadila's consumer goods business, which included sugar substitute brand Sugar Free and EverYuth range of skincare products, into Carnation. [11] The merged entity was then named as Zydus Wellness Limited in January 2009. [12] [13]
From Wikipedia, the free encyclopedia. Redirect page
He took charge in 1995 after a formal separation between the two founding families from Zydus Cadila to Zydus Lifesciences and Cadila Healthcare. [7] When he took over the Cadila Healthcare, he was faced with two challenges: His was a Rs 200-crore company whereas his overheads including management, research, company expenses, and staff worked ...
A study called The Indian Polycap Study (TIPS) was sponsored by Cadila Pharmaceuticals Limited, (where the drug development program was coordinated by JP Parswani, President, and Dr. Arun Maseeh, Vice-President Medical Affairs), and led by Dr. Salim Yusuf of McMaster University in Hamilton, Ontario, and Dr. Prem Pais of St. John's Medical College in Bangalore, India.